Claudia Dufke

Dr. Claudia Dufke

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2024 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KFKarla P. Figueroa
Karla P. Figueroa
CGCaspar Gross
Caspar Gross
EBElena Buena-Atienza
Elena Buena-Atienza
SPSharan Paul
Sharan Paul
MGMandi Gandelman
Mandi Gandelman
SPStefan M. Pulst
Stefan M. Pulst

7 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
LGLucas Caldi Gomes
Lucas Caldi Gomes
SHSonja Hänzelmann
Sonja Hänzelmann
FHFabian Hausmann
Fabian Hausmann
RKRobin Khatri
Robin Khatri
SOSergio Oller
Sergio Oller
Paul LingorPaul Lingor
Paul Lingor
Amyotrophic lateral sclerosis (ALS) is a debilitating motor neuron disease and lacks effective disease-modifying treatments. This study utilizes a comprehensive multiomic approach to investigate the early and sex-specific molecular mechanisms underlying ALS. By analyzing the prefrontal cortex of 51 patients with sporadic ALS and 50 control subjects, alongside four transgenic mouse models (C9orf72-, SOD1-, TDP-43-, and FUS-ALS), we have uncovered significant molecular alterations associated with the disease. Here, we show that males exhibit more pronounced changes in molecular pathways compared to females. Our integrated analysis of transcriptomes, (phospho)proteomes, and miRNAomes also identified distinct ALS subclusters in humans, characterized by variations in immune response, extracellular matrix composition, mitochondrial function, and RNA processing. The molecular signatures of human subclusters were reflected in specific mouse models. Our study highlighted the mitogen-activated protein kinase (MAPK) pathway as an early disease mechanism. We further demonstrate that trametinib, a MAPK inhibitor, has potential therapeutic benefits in vitro and in vivo, particularly in females, suggesting a direction for developing targeted ALS treatments.

16 November 2020 in Movement Disorders
Verified
Journal Article
Open access
PDF file
MWMarlous C.M. van der Weijden
Marlous C.M. van der Weijden
DRDayana Rodriguez‐Contreras
Dayana Rodriguez‐Contreras
CDCathérine C.S. Delnooz
Cathérine C.S. Delnooz
BRBrooks G. Robinson
Brooks G. Robinson
ACAlec F. Condon
Alec F. Condon
DVD.S. Verbeek
D.S. Verbeek
Background: We describe a 4‐generation Dutch pedigree with a unique dominantly inherited clinical phenotype of a combined progressive chorea and cervical dystonia carrying a novel heterozygous dopamine D2 receptor (DRD2) variant.Objectives: The objective of this study was to identify the genetic cause of the disease and to further investigate the functional consequences of the genetic variant.Methods: After detailed clinical and neurological examination, whole‐exome sequencing was performed. Because a novel variant in the DRD2 gene was found as the likely causative gene defect in our pedigree, we sequenced the DRD2 gene in a cohort of 121 Huntington‐like cases with unknown genetic cause (Germany). Moreover, functional characterization of the DRD2 variant included arrestin recruitment, G protein activation, and G protein‐mediated inhibition of adenylyl cyclase determined in a cell model, and G protein‐regulated inward‐rectifying potassium channels measured in midbrain slices of mice.Result: We identified a novel heterozygous variant c.634A > T, p.Ile212Phe in exon 5 of DRD2 that cosegregated with the clinical phenotype. Screening of the German cohort did not reveal additional putative disease‐causing variants. We demonstrated that the D2S/L‐I212F receptor exhibited increased agonist potency and constitutive activation of G proteins in human embryonic kidney 239 cells as well as significantly reduced arrestin3 recruitment. We further showed that the D2S‐I212F receptor exhibited aberrant receptor function in mouse midbrain slices.Conclusions: Our results support an association between the novel p.Ile212Phe variant in DRD2, its modified D2 receptor activity, and the hyperkinetic movement disorder reported in the 4‐generation pedigree. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

21 September 2013 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
JCJohanna Christina Czeschik
Johanna Christina Czeschik
PBPeter Bauer
Peter Bauer
KBKarin Buiting
Karin Buiting
CDClaudia Dufke
Claudia Dufke
EGEncarna Guillén-Navarro
Encarna Guillén-Navarro
AKAlma Kuechler
Alma Kuechler
X-linked intellectual disability type Nascimento (MIM #300860), caused by mutations in UBE2A (MIM *312180), is characterized by craniofacial dysmorphism (synophrys, prominent supraorbital ridges, deep-set, almond-shaped eyes, depressed nasal bridge, prominent columella, hypoplastic alae nasi, and macrostomia), skin anomalies (hirsutism, myxedematous appearance, onychodystrophy), micropenis, moderate to severe intellectual disability (ID), motor delay, impaired/absent speech, and seizures. Hitherto only five familial point mutations and four different deletions including UBE2A have been reported in the literature. We present eight additional individuals from five families with UBE2A associated ID - three males from a consanguineous family, in whom we identified a small deletion of only 7.1 kb encompassing the first three exons of UBE2A, two related males with a UBE2A missense mutation in exon 4, a patient with a de novo nonsense mutation in exon 6, and two sporadic males with larger deletions including UBE2A. All affected male individuals share the typical clinical phenotype, all carrier females are unaffected and presented with a completely skewed X inactivation in blood. We conclude that 1.) X-linked intellectual disability type Nascimento is a clinically very distinct entity that might be underdiagnosed to date. 2.) So far, all females carrying a familial UBE2A aberration have a completely skewed X inactivation and are clinically unaffected. This should be taken in to account when counselling those families. 3.) The coverage of an array should be checked carefully prior to analysis since not all arrays have a sufficient resolution at specific loci, or alternative quantitative methods should be applied not to miss small deletions.

6 January 2022 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
LHLaura Herrmann
Laura Herrmann
MGMathias Gelderblom
Mathias Gelderblom
MBMaxim Bester
Maxim Bester
NDNatalie Deininger
Natalie Deininger
TSThorsten Schütze
Thorsten Schütze
SZSimone Zittel
Simone Zittel

14 February 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
BMBenita Menden
Benita Menden
RERana D. Incebacak Eltemur
Rana D. Incebacak Eltemur
GDGerman Demidov
German Demidov
MSMarc Sturm
Marc Sturm
JPJoohyun Park
Joohyun Park
THTobias Haack
Tobias Haack
Most patients with a rare movement disorder (MD) do not receive a molecular diagnosis, and the underlying genetic variants and mediating genes remain elusive. Here, we evaluate the diagnostic accuracy of conventional and next-generation sequencing-based genetic testing strategies in a cohort of 2,811 individuals with ataxia, spastic paraplegia and dystonia. Exome sequencing establishes genetic diagnoses in 19.3% of cases, and specificity of phenotypic features and age at testing are positive predictors. Genome analysis ‘beyond the exome’ increases the diagnostic yield by 7.5%, mostly due to the improved detection of structural variants and repeat expansions. Unsolved cases are included in the Solve-RD cohort and subjected to gene-burden analysis, providing evidence for loss-of-function variants in X-chromosomal CD99L2 causing spastic ataxia. Cellular studies show that the transmembrane protein CD99L2 occurs mainly in a ubiquitinated form and serves as an activating interactor of the calcium-dependent protease CAPN1. Ablation of cytoplasmic or extracellular domains of CD99L2 leads to its intracellular mislocalization and abrogation of its interplay with CAPN1. Transcriptome analysis in CD99L2 patient-derived fibroblasts reveals synaptic function-specific disturbances. Impaired CAPN1 activation and dysregulation of downstream neuronal pathways constitute the likely molecular cause for neurodegeneration.